The Agenda is preliminary one to meet the current track settings. With more international renowned institution joining the congress, special session and new sessions either sponsored or requested from scientific and industrial communities will be released when enough high profile speakers are
Confirmed. Due to the financial restrictions or visa applications issues to international delegates from many countries, even those confirmed speakers, they may not eventually present at the congress. In that case, some unfilled sessions will be combined later to save space for other demanded topics. So, the official agenda will be finalized two week earlier on Meeting Guide and congress booklet.
Time |
Room
No. |
Friday 10/17/2008 |
Saturday
10/18/2008 |
Sunday
10/19/2008 |
Monday
10/20/2008 |
Tuesday
10/21/2008 |
Wednesday
10/22/2008 |
10/24-25/2008 |
8:00-8:30 |
|
|
Onsite Registration |
Medichem Symposium |
Track 2 |
Track 4 |
Track 6 |
Tech Tour to Xian |
8:30-10:10 |
1 |
Registration
(All Day)
Lobby of the Hotel
|
1. Group Photo
2. Opening Ceremony
3. Keynote Forum |
Plenary Lectures
-- From Novel Targets to Billion Dollar Molecules
Special Symposium Sponsored by ACS-Medichem Division
|
Session 21
New Interventions in Drug Discovery: From Bench to Clinic |
Session 41
HPV and Other Antiviral Drug Discovery and Development |
Session 61
Drug R & D Licensing and Partnering in China -From CRO to FTE
|
|
2 |
Session 22
Modeling, SAR and Synthesis |
Session 42
Antifungal Drug Discovery and Development |
Session 62
Find your CMO by Integrating China Tech Resources for Cost Effective Biologics |
|
3 |
Session 23
Combinatorial and High Throughput Synthetic Chemistry |
Session 43
Cardiovascular Drug Discovery and Development |
Session 63
Huge Talent Chemist Pool for Outsourcing Medicinal Chemistry |
|
4 |
Session 24
Target Identification and Lead Optimization |
Session 44
Neurodegenerative Diseases Drug Discovery and Development |
Session 64
Increase Your Labor Threshold of Preclinical and Clinical Trials in China |
|
5 |
Session 25
Pharmaceutical Outsourcing |
Session 45
Metabolic Diseases Drug Discovery and Development |
Session 65
Joint Venture on Screening Natural Formulation from Efficacy Validated T |
|
10:10-10:30
Coffee Break |
|
Track 3
After Coffee Break |
Track 4
After Coffee Break |
Post-Conferences
After Coffee Break |
|
|
6 |
Session 26
RNAi, MicroRNA, and Non-Coding RNA Technologies |
Session 46
Asthma/COPD Drug Discovery and Development |
Workshop 4
New Paradigm of Alliance /Collaborative Drug Discovery with Academia in China
|
|
10:30-12:10 |
7 |
Session 27
Bioinformatics, Bio-IT, LIMS to Data Visualization in Drug Discovery |
Session 47
Autoimmune Disorder Drug Discovery and Development |
Workshop 5
How to Meet FDA Requirement by Performing Effective Clinical Trials for INDs in China |
|
8 |
Session 28
Computer Aided Drug Design and Fragment-Based Discovery |
Session 48
Anti-Allergy Drug Discovery and Development |
Workshop 6
Botanical Drugs: Production, Analyses and FDA Regulations |
|
9 |
Session 29
Multiple Read-Out Options, Biochips, Microarray, Electrophoresis, Lab-on-Chips and Lab Automation |
Session 49
MDR Drug Resistant Bacterial/Parasite Infections, TB and Malaria
|
6 th IDDST
Closed |
|
10 |
Session 30
High Throughput/Content and Virtual Screening
|
Session 50
Drug Discovery and Development against Severe Gastrointestinal Disorders |
|
12:10-13:10 |
Launch Break |
| |
|
Pre-Conferences |
Track 1 |
Track 1 |
Track 3 |
Track 4 |
Tech Tour
in Beijing
10/22-23/2008 |
Tech Tour to Xian |
| 13:10-15:10 |
1 |
Workshop 1
How to File IND with China SFDA |
Session 1
Session 1: ^-Omics ̄, Molecular Genetics to System Biology in Drug Discovery |
Session 11
Protein/Peptide Sciences, and Protein-Protein Interactions |
Session 31
Technologies from Enzyme to Cell Based Assays |
Session 51
Novel Regenerative Medicine Therapeutics and Stem Cell Therapies |
|
|
| |
2 |
Workshop 2
What Policy Privilege for Foreign Inventor to Develop Biopharmaceuticals in China |
Session 2
Regenerative Medicine in Drug Discovery |
Session 12
Molecular Targets and Biomarkers in Drug Discovery |
Session 32
Translational Medicines
|
Session 52
Alternative Cell Therapeutics Discovery and Development |
|
|
| |
3 |
Workshop 3
Opportunities and Challenges upon Off-Patent Blockbusters |
Session 3
Molecular/Cell Biology and Drug Discovery |
Session 13
Cytokine based Drug Discovery |
Session 33
LC, LC-MS, NMR and X-ray Crystallography in Drug Discovery |
Session 53
Therapeutic Monoclonal Antibody Development |
|
|
| |
4 |
|
Session 4
Immunology and Drug Discovery |
Session 14
Protein to Cell Based Assay Technologies |
Session 34
Safety Evaluation Tech: From ADME-Tox Screening to Clinical Trials |
Session 54
New Preventive and Therapeutic Vaccine Discovery and Development |
|
|
| |
5 |
|
Session 5
Oncology and Drug Discovery |
Session 15
Nuclear Receptors and Drug Discovery |
Session 35
Nanotechnologies and Novel Drug Delivery Technologies |
Session 55
Gene Therapeutics / Nucleic Acid Based Drug Discovery and Development |
|
|
15:10-15:30
Coffee Break |
|
|
Track 1
After Coffee Break |
Track 1
After Coffee Break |
Track 4
After Coffee Break |
Track 5
After Coffee Break |
|
|
| 15:30-17:30 |
6 |
|
Session 6
Microbiology, Virology in Drug Discovery |
Session 16
Proteinase and Kinases in Drug Discovery |
Session 36
Anti-Emerging Disease Drug Discovery and Development |
Session 56
Apply Cutting edge Technologies For Modernization of TCM |
|
|
| |
7 |
|
Session 7
Neurology in Drug Discovery |
Session 17
G Protein-Coupled Receptors in Drug Discovery |
Session 37
Cancer Therapeutics Discovery and Development |
Session 57
Rethink TCM in System Biology and Multi-Target Theory |
|
|
| |
8 |
|
Session 8
Hepatology in Drug Discovery |
Session 18
Targeting Signaling Pathways |
Session 38
CNS Disorder Drug Discovery and Development |
Session 58
Mining Hits and Leads using TCM as Super Natural Compound Library |
|
|
| |
9 |
|
Session 9
Endocrinology in Drug Discovery |
Session 19
Laboratory Animals in Drug Discovery |
Session 39
Anti-HIV Drug Discovery and Development |
Session 59
Develop Bioprocesses for Production of High Value Natural Medicines |
|
|
| |
10 |
|
Session 10
Pharmacology, Toxicology and Pathology in Drug Discovery |
Session 20
Clinical Trials Methodologies |
Session 40
Anti-HCV Drug Discovery and Development |
Session 60
Establish Standardized and Quantitative TCM Formulation |
|
|
18:30-9:00 |
|
|
Welcome Banquet |
Social Dinner |
Social Dinner |
Social Dinner |
|
|